From Investing.com: 2024-04-15 20:11:06

Regeneron Pharmaceuticals is fighting back against a U.S. Department of Justice complaint claiming it misreported Eylea’s average sales price. The company argues reimbursing credit card fees isn’t a price concession. The DOJ alleges Regeneron failed to report funds used to subsidize Eylea purchases. Eylea is FDA-approved for treating conditions like wet age-related macular degeneration.



Read more at Investing.com: Regeneron to defend against DOJ complaint on drug-price manipulation By Reuters